诚信认证：
工商注册信息已核实！
快速导航
产品分类
微信二维码
Minisite
QQ号咨询
激酶
Brivanib (BMS-540215)
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
产品参数
| 货号 | CAS号 | 操作 |
|---|---|---|
| B127317-50mg | 649735-46-6 | 询价 |
| B127317-5mg | 649735-46-6 | 询价 |
| B127317-10mg | 649735-46-6 | 询价 |
产品介绍
- 分子式 C19H19FN4O3
- 分子量370.39
属性
| 溶解性 | Soluble in DMSO (74 mg/ml at 25 °C), water (<1 mg/ml at 25 °C), and ethanol (3 mg/ml at 25 °C). |
| 存贮条件 | 储存温度-20°C |
描述
| 应用 | An ATP-competitive inhibitor against VEGFR-2, Flk-1, VEGFR-1 and FGFR-1 |
| 产品介绍 | Brivanib (BMS-540215)是一种ATP竞争性的VEGFR2抑制剂，IC50为25 nM，对VEGFR-1和FGFR-1抑制作用适中，但比作用于PDGFR-β效果强240多倍。 |
| 备注 | Brivanib is an ATP-competitive inhibitor against VEGFR2 with IC50 of 25 nM, moderate potency against VEGFR-1 and FGFR-1, but >240-fold against PDGFR-β. Phase 3. |
| 生化机理 | Brivanib is an ATP-competitive inhibitor against human VEGFR-2 and mouse Flk-1 with IC50 of 25 nM and 89 nM, respectively. Brivanib also inhibits VEGFR-1 and FGFR-1 with IC50 of 0.38 and 0.148 μM. Brivanib displays antitumor activities in H3396 xenograft. This compound completely inhibits the tumor growth, with TGI of 85% and 97%, respectively. |
| 别名 | 1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基]氧基]-2-丙醇; 酪氨酸激酶抑制剂;BMS-540215; BMS540215; BMS 540215;(2R)-1-[4-(4-Fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4 ]triazin-6-yloxy]propanol |
Brivanib (BMS-540215)信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于Brivanib (BMS-540215)报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途